Tadalafil for PAH: PHIRST Clinical Trial
{"Image DocumentName": "Tadalafil for PAH: PHIRST Clinical Trial", "Image ImageDescription": "Study Results. Efficacy. Greater improvement in 6-MWD in treatment-na\u00efve patients compared to patients with background bosentan. Significant improvements in quality of life and time to and incidence of clinical worsening (68% relative risk reduction) Safety. Most common adverse events were headache, myalgia, and flushing which were mild to moderate in severity. Covers learning objective 3) Use evidence-based guidelines to select the most appropriate treatment. Covers learning objective 5) Compare the side effect profiles and drug interaction potential of available PAH treatments to gauge the risk-benefit ratio of each option and to determine areas for patient monitoring. The findings from the PHIRST clinical trial included greater improvement in 6-MWD in treatment-na\u00efve patients compared to patients with background bosentan therapy. In addition, patients demonstrated significant improvements in quality of life and time to and incidence of clinical worsening. The most common adverse events reported were headache, myalgia, and flushing. All adverse events were considered mild to moderate in severity. Galie, et al. Circulation. 2009;Epub May 26. Pepke-Zaba, et al. Curr Med Res Opin. 2009;25(10):", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}